VERVE THERAPEUTICS INC (VERV)

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular disease. The company is headquartered in Boston, Massachusetts and currently employs 204 full-time employees. The company went IPO on 2021-06-17. The Company’s programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. The company is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second product candidate VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a regulator of cholesterol and triglyceride metabolism.

Company Info

VERVE THERAPEUTICS INC

201 Brookline Avenue, Suite 601

Boston MASSACHUSETTS

P: 19785013026

CEO: Sekar Kathiresan

Employees: 204

Website: https://www.vervetx.com/